Core Viewpoint - Citigroup maintains a "Buy" rating for Yidu Tech (02158) and raises its target price to HKD 11, indicating a potential upside of over 96% for the stock [1] Group 1: Company Positioning - Yidu Tech is positioned as a leading player in the domestic AI healthcare sector, leveraging favorable policies, deep industry experience, and a comprehensive product layout to secure a core position in the wave of healthcare AI infrastructure development [1] - The company has embedded itself in national AI healthcare application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions through products like Doctor Copilot [1] Group 2: Policy and Market Opportunities - The macro policy push for "AI + Healthcare" in China provides a clear growth path for Yidu Tech, with plans to establish multiple national pilot bases by 2027 and achieve widespread AI technology coverage in secondary hospitals by 2030 [1] - The company's WeChat mini-program "Yidu Qianyu" demonstrates strong technical capabilities, ranking alongside top products in accuracy and traceability, thus supporting both To-G (government and hospitals) and To-C (consumer) business models [1] Group 3: Financial Projections - Citigroup recognizes Yidu Tech's substantial accumulation in medical data governance and knowledge construction, attributing unique advantages to the quality and authority of its data sourced from top hospitals [2] - The company's To-G business segment shows more predictable profitability compared to consumer applications, benefiting directly from increased hospital AI budgets and national project tenders [2] - Financial forecasts have been adjusted, with expectations for the big data platform revenue to grow by 17% and 30% year-on-year in fiscal years 2026 and 2027, respectively, with a potential break-even point in fiscal year 2026 [2]
花旗研报：医渡科技(02158)AI技术及业务壁垒深厚 目标价上调至11港元